Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

Nine randomized controlled trials which compared rivaroxaban to enoxaparin for thromboprophylaxis in total knee and total hip arthroplasty were selected for inclusion. Meta-analysis was performed for incidences of symptomatic venous thromboembolism (VTE), major bleeding, clinically-relevant non-major bleeding, all-cause mortality, and postoperative wound infection. Trial sequential analysis was also performed to supplement results on incidence of symptomatic VTE and major bleeding events. Results demonstrated a significantly lower rate of symptomatic VTE, particularly symptomatic deep vein thrombosis, with rivaroxaban versus enoxaparin, but also a significantly higher incidence of major bleeding events. Trial sequential analysis demonstrated required information size for symptomatic VTE had been met and suggested that further data would unlikely change results, whereas required information size for data on major bleeding had not been met, and further data was needed regarding this outcome.